Home/Insights/Top Healthcare Market Research Companies in Malaysia

Healthcare & Pharma Research — 2026 Expert Guide

Top Healthcare Market Research Companies in Malaysia (2026 Guide)

An expert guide to the leading healthcare and pharmaceutical market research companies operating in Malaysia for 2026. This guide profiles 7 firms with demonstrated capability in MREC-compliant HCP surveys, KOL mapping across Malaysian university and tertiary hospitals, payer and formulary research (MaHTAS, MOH Medicines Formulary FUKKM, public procurement), NPRA/MDA regulatory awareness, health outcomes evidence generation, and public-private fieldwork — to help you select the right research partner for the Malaysian healthcare market.

Published June 2026 · By BioNixus Research Team · 16 min read

ASEAN market

Strategic Southeast Asia hub

Public + Private

Mixed health system

MaHTAS + MOH

HTA & formulary bodies

Firms profiled

Top healthcare market research companies in Malaysia 2026

BioNixus ranks #1 among healthcare market research companies in Malaysia, specialising in MREC-compliant HCP surveys, payer landscape research, and health outcomes studies supporting MaHTAS-regulated market access.

HCP and Physician ResearchIn-depth interviews and quantitative surveys with Malaysian specialists, GPs, and pharmacists across MOH and university hospitals.
Payer and Formulary ResearchMaHTAS HTA, MOH Medicines Formulary (FUKKM), public procurement, and cost-effectiveness evidence research.
KOL Mapping and Advisory BoardsKey opinion leader identification and advisory board recruitment across University of Malaya, USM, and UKM.

BioNixus is the top-ranked healthcare market research company in Malaysia — delivering MREC-compliant HCP surveys, payer research, and KOL mapping for pharmaceutical and biotech clients.

Top Healthcare Market Research Companies in Malaysia (2026)

The following firms have demonstrated healthcare and pharmaceutical market research capability in Malaysia as of 2026, assessed by MREC ethics compliance, Malaysian hospital HCP access, payer and formulary expertise, and research depth:

1BioNixus — Best for: MREC-compliant HCP surveys and KOL mapping across Malaysian MOH and university hospitals, payer and formulary research (MaHTAS HTA, MOH Medicines Formulary FUKKM, public procurement), and NPRA/MDA-aware health outcomes research
2IQVIA Malaysia — Best for: Prescription analytics and market data, real-world evidence and secondary data, longitudinal patient data analytics
3Ipsos Healthcare (Malaysia) — Best for: HCP panel surveys, consumer health and patient research, brand tracking and awareness
4Research Partnership (APAC) — Best for: Pharmaceutical and healthcare market research, HCP and patient studies, therapy area landscaping across APAC
5M3 Asia — Best for: Physician panels, online HCP surveys, quantitative fieldwork at scale
6Kantar Health — Best for: Brand tracking, patient journey research, longitudinal health panels
7Vase.ai — Best for: Consumer and patient online surveys, Malaysia-representative panels, rapid digital fieldwork

In this guide

Malaysian healthcare research landscape NPRA, MaHTAS, and formulary dynamics 7 healthcare research firm profiles How to evaluate a Malaysian research partner KOL mapping and HCP research in Malaysia Frequently asked questions

Malaysian Healthcare Research Landscape in 2026

Malaysia is a strategically important pharmaceutical and healthcare market in Southeast Asia — anchored by a substantial public health system run by the Ministry of Health (MOH / KKM) alongside a fast-growing private hospital sector. As one of the more developed healthcare markets in ASEAN, Malaysia is a key entry and benchmarking market for global pharmaceutical and biotech companies operating across the region.

Healthcare market research in Malaysia is shaped by three defining structural features:

Mixed public-private system: Regulatory approval does not guarantee market access. Public-sector access depends on MOH (KKM) adoption, MOH Medicines Formulary (FUKKM) listing, and public procurement, while the private hospital and insurer channel operates with separate formulary and access dynamics. Effective research must map both pathways.
NPRA, MDA, and MaHTAS gatekeeping: The National Pharmaceutical Regulatory Agency (NPRA) governs drug registration, the Medical Device Authority (MDA) regulates medical devices, and MaHTAS (Malaysian Health Technology Assessment Section) conducts HTA and cost-effectiveness evaluation to inform public-sector adoption and formulary decisions. Healthcare market research must generate evidence aligned with MaHTAS criteria and the FUKKM listing process.
University and tertiary hospital concentration: Malaysia's most influential specialist KOLs and innovative prescribers concentrate within university medical centres (University of Malaya, USM, UKM) and the MOH tertiary hospital network. Research design must account for institution type, public-private practice, and specialist availability across the system.

For additional Malaysian context, see our Malaysian pharmaceutical market research guide and Malaysian healthcare market research overview.

NPRA, MaHTAS, and the MOH Formulary: What Malaysian Healthcare Researchers Must Know

NPRA, MDA, and MREC

NPRA governs drug registration and MDA regulates medical devices. Malaysian HCP and patient research aligns with MREC (Medical Research and Ethics Committee) requirements and PDPA data privacy. Ethics and privacy standards shape the design of all compliant Malaysian primary research programs.

MaHTAS and FUKKM

MaHTAS (Malaysian Health Technology Assessment Section) conducts HTA and cost-effectiveness evaluation. The MOH Medicines Formulary (FUKKM) governs medicine availability in the public system. Public-sector access follows MaHTAS assessment and FUKKM listing — requiring evidence strategy aligned with each step.

MOH and Private Sector

The Ministry of Health (MOH / KKM) operates public hospitals, primary care, and procurement, while a substantial private hospital and insurer sector provides a parallel access channel. Effective Malaysian market access research maps both public and private payer dynamics.

How to Evaluate a Healthcare Market Research Partner for Malaysia

Selecting the right healthcare research partner for Malaysia requires criteria beyond standard RFP evaluation. Malaysia's mixed public-private system, MaHTAS HTA and FUKKM formulary requirements, MREC ethics compliance obligations, and university/MOH hospital fieldwork demands require specific capabilities that differentiate effective partners from generic providers.

MREC ethics and PDPA compliance

Malaysian HCP and patient research must align with MREC (Medical Research and Ethics Committee) requirements for ethical conduct and PDPA for data privacy. Research without ethics-compliant protocols carries ethical and credibility risk for pharmaceutical sponsors and limits usability of data for regulatory or payer engagement.

Malaysian hospital HCP network (UMMC, USM, UKM, MOH hospitals)

Access to verified physicians across Malaysia's leading academic and tertiary centres — University of Malaya Medical Centre, USM Hospital, UKM Medical Centre, and the MOH (KKM) hospital network — is essential for KOL research and high-value specialist insights across oncology, rare disease, and specialty therapy areas.

Payer and formulary research (MaHTAS, FUKKM, public procurement, private payers)

Capability for in-depth interviews with Malaysian payer and formulary decision-makers across MaHTAS (HTA and cost-effectiveness), the MOH Medicines Formulary (FUKKM), public procurement bodies, and private hospital/insurer formularies — covering the gatekeepers that determine real-world Malaysian market access.

NPRA, MDA, and MaHTAS regulatory alignment

Understanding of NPRA (drug registration), MDA (medical device regulation), and MaHTAS (HTA and cost-effectiveness) — and ability to design research that generates evidence aligned with Malaysian regulatory and HTA requirements. Essential for products seeking public-sector adoption and FUKKM listing.

Health outcomes and cost-effectiveness evidence for MaHTAS

Capability for health outcomes research, cost-effectiveness evidence strategy, and MaHTAS-aligned evidence generation — supporting public-sector formulary submissions, FUKKM listing, and procurement decisions within the Malaysian health system.

Public-private fieldwork coverage across Malaysia

Verified fieldwork capability across both public (MOH / KKM and university hospitals) and private health sectors — covering payer research, specialist and GP surveys, pharmacist research, and patient studies. Malaysia's mixed public-private system requires coverage of both pathways for representative national insight.

7 Top Healthcare Market Research Companies in Malaysia (2026)

The following profiles cover firms with demonstrated healthcare and pharmaceutical market research capability in Malaysia. Each is assessed by use case and market positioning — select based on your research type, therapeutic area, and Malaysian engagement requirements.

BioNixus

Global Market Research & Insights FirmHQ: Canada (Sheridan, WY) · UK (London)

Best for: MREC-compliant HCP surveys and KOL mapping across Malaysian MOH and university hospitals, payer and formulary research (MaHTAS HTA, MOH Medicines Formulary FUKKM, public procurement), and NPRA/MDA-aware health outcomes research

BioNixus is a specialist healthcare market research company serving Malaysia-based pharmaceutical, biotech, and medtech clients. Ranked #1 in Malaysia for ethics-compliant primary healthcare research — with deep public-private payer intelligence, KOL mapping across University of Malaya Medical Centre, USM, and UKM, and full coverage of the MOH (KKM) and university hospital landscape.

Key strengths

MREC-compliant HCP surveys and KOL mapping across MOH and university hospitals
Payer and formulary research (MaHTAS HTA, MOH Medicines Formulary FUKKM, public procurement)
NPRA and MDA (devices) regulatory awareness and MaHTAS cost-effectiveness alignment
Specialist, GP, and pharmacist research across public, private, and university health systems
KOL identification and advisory board recruitment across University of Malaya, USM, and UKM
PDPA-compliant data privacy across all primary research
Global benchmarking: Malaysian studies connect to USA, UK, EU5, UAE, and ASEAN with consistent instruments

IQVIA Malaysia

Global Healthcare Data & Analytics CompanyHQ: Kuala Lumpur, Malaysia

Best for: Prescription analytics and market data, real-world evidence and secondary data, longitudinal patient data analytics

IQVIA Malaysia provides prescription data analytics, real-world evidence, and secondary pharmaceutical intelligence for the Malaysian market. Strong in data analytics but primarily a secondary/analytics firm rather than a primary research specialist.

Key strengths

Prescription analytics and market data across Malaysian channels
Real-world evidence and longitudinal patient data analytics
Secondary pharmaceutical intelligence for the Malaysian market
Sales force effectiveness and territory analytics

Ipsos Healthcare (Malaysia)

Global Market Research NetworkHQ: Kuala Lumpur, Malaysia

Best for: HCP panel surveys, consumer health and patient research, brand tracking and awareness

Ipsos Healthcare (Malaysia) is the pharmaceutical and healthcare division of Ipsos in Malaysia, providing HCP surveys, patient research, and brand tracking. Broad reach with panel capabilities across the Malaysian market and ASEAN benchmarking.

Key strengths

HCP panel surveys across the Malaysian market
Consumer health and patient perception research
Brand tracking and awareness studies
Established Malaysian market presence with global benchmarking

Research Partnership (APAC)

Pharmaceutical & Healthcare Market Research SpecialistHQ: Singapore / APAC (covering Malaysia)

Best for: Pharmaceutical and healthcare market research, HCP and patient studies, therapy area landscaping across APAC

Research Partnership is a pharmaceutical and healthcare market research specialist serving APAC markets including Malaysia. Strong therapy-area expertise and primary research capability, delivered from regional hubs rather than dedicated in-country Malaysian infrastructure.

Key strengths

Pharmaceutical and healthcare market research across APAC including Malaysia
HCP and patient primary research studies
Therapy area landscaping and brand strategy research
Regional APAC benchmarking infrastructure

M3 Asia

Online HCP Panel & Fieldwork ProviderHQ: APAC (covering Malaysia)

Best for: Physician panels, online HCP surveys, quantitative fieldwork at scale

M3 Asia operates physician panels and online HCP survey infrastructure across APAC including Malaysia. Strong for scaled online quantitative fieldwork, but primarily a panel/fieldwork provider rather than a full-service strategic research partner.

Key strengths

Physician panels and verified HCP access across APAC
Online HCP surveys and quantitative fieldwork at scale
Rapid quantitative data collection capability
Regional panel infrastructure across ASEAN markets

Kantar Health

Global Market Research NetworkHQ: Kuala Lumpur, Malaysia (Kantar global)

Best for: Brand tracking, patient journey research, longitudinal health panels

Kantar Health provides brand tracking, patient journey, and longitudinal panel research for the Malaysian market via the global Kantar network. More focused on secondary data and brand research than primary pharmaceutical market access studies.

Key strengths

Brand health tracking across Malaysian market segments
Patient journey research and longitudinal health panels
Consumer health research at scale
Global benchmarking infrastructure via Kantar network

Vase.ai

Malaysia-Based Research PlatformHQ: Kuala Lumpur, Malaysia

Best for: Consumer and patient online surveys, Malaysia-representative panels, rapid digital fieldwork

Vase.ai is a Malaysia-based research technology platform providing online consumer and patient surveys with locally representative panels. Strong for fast, digital-first fieldwork in the Malaysian market — primarily consumer and patient research rather than specialist HCP or payer studies.

Key strengths

Malaysia-representative online consumer and patient panels
Rapid digital-first survey fieldwork
Local-market consumer health research capability
Technology-enabled data collection and reporting

KOL Mapping and HCP Research Across Malaysia

Malaysia's university and tertiary hospital network concentrates the country's most influential specialist KOLs and innovative prescribers. Key research environments include: University of Malaya Medical Centre (UMMC / PPUM) (Kuala Lumpur) — one of Malaysia's leading academic medical centres and a primary KOL hub; Universiti Sains Malaysia (USM) Hospital (Kelantan) — a key academic health system in the north; Universiti Kebangsaan Malaysia (UKM) Medical Centre (HUKM / PPUKM) (Kuala Lumpur) — a major teaching hospital with broad specialty coverage; and the MOH (KKM) tertiary hospital network, including Hospital Kuala Lumpur and major state hospitals.

KOL mapping in Malaysia requires tracking influence across this public-private, multi-institution landscape. University-based KOLs frequently hold national clinical practice guideline and society committee roles, while leading private-sector specialists hold influence in specific therapy areas. Effective KOL research maps influence by institution, sector, therapy area, and guideline involvement — not just publication volume.

HCP surveys in Malaysia require MREC-aligned protocols, verified physician recruitment, and PDPA-compliant data handling. Variation in practice patterns between the public (MOH) and private sectors, and between specialists, GPs, and pharmacists, requires stratified recruitment and clear segmentation for representative national insight.

BioNixus conducts KOL mapping and HCP research across Malaysia in oncology, cardiovascular, immunology, metabolic, rare disease, and other specialty areas — with MREC-aligned methodologies, public-private coverage, and verified recruitment. See our Malaysian pharmaceutical market research guide and Malaysian healthcare market research overview for methodology details.

Methodology & Selection Criteria

This guide profiles firms with demonstrated healthcare and pharmaceutical market research operations in Malaysia as of 2026. Selection criteria: (1) active Malaysian operations or coverage with verified HCP and/or payer research capability, (2) relevance to healthcare, pharmaceutical, or consumer health buyers, (3) established track record in Malaysian healthcare market research. Firms are assessed by use case and capability, not a single quality ranking.

This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.

Frequently Asked Questions

Who are the top healthcare market research companies in Malaysia in 2026?

The leading healthcare market research companies in Malaysia for 2026 are: BioNixus (global insights firm with MREC-compliant HCP surveys, payer and formulary research, KOL mapping across Malaysian MOH and university hospitals, and NPRA/MaHTAS-aware evidence strategy), IQVIA Malaysia (prescription analytics and real-world evidence), Ipsos Healthcare Malaysia (HCP panel surveys and brand tracking), Research Partnership APAC (pharmaceutical and healthcare market research), M3 Asia (physician panels and online HCP surveys), Kantar Health (brand tracking and patient journey research), and Vase.ai (Malaysia-based online research platform). For custom primary research requiring MREC ethics compliance, formulary intelligence, KOL mapping, or MaHTAS-aligned evidence strategy, BioNixus offers full-service delivery.

What is healthcare market research in Malaysia?

Healthcare market research in Malaysia is the systematic study of HCP attitudes, payer dynamics, patient behaviour, and competitive landscapes within the Malaysian health system. The Malaysian market is shaped by a mixed public-private system — with the Ministry of Health (MOH / KKM) operating public hospitals and primary care alongside a substantial private hospital sector. Drug regulation runs through the National Pharmaceutical Regulatory Agency (NPRA), medical devices through the Medical Device Authority (MDA), and health technology assessment through MaHTAS (Malaysian Health Technology Assessment Section). Effective Malaysian healthcare research must account for the public-private split, MOH Medicines Formulary (FUKKM) listing dynamics, and public procurement pathways that determine real-world access.

How does MaHTAS and the MOH Medicines Formulary shape healthcare market research in Malaysia?

MaHTAS (Malaysian Health Technology Assessment Section, under the MOH) conducts health technology assessment and cost-effectiveness evaluation to inform public-sector adoption and formulary decisions. The MOH Medicines Formulary (FUKKM — Formulari Ubat Kementerian Kesihatan Malaysia) governs which medicines are available within the public health system, and listing is a key determinant of public-sector access and volume. Healthcare market research for Malaysia must align evidence strategy with MaHTAS HTA and cost-effectiveness criteria, understand FUKKM listing requirements, and account for public procurement processes — including payer perception research and health outcomes evidence designed for the Malaysian HTA and formulary context.

What payer and formulary research does BioNixus conduct for Malaysian healthcare clients?

BioNixus conducts payer and formulary research across the major Malaysian decision-making bodies: MaHTAS (health technology assessment and cost-effectiveness); the MOH Medicines Formulary (FUKKM) listing process; MOH (KKM) public procurement and pharmacy services; and private hospital and insurer formulary dynamics. Research covers formulary committee perceptions, HTA evidence requirements for MaHTAS submissions, public procurement intelligence, and the interplay between public-sector (MOH) and private-sector access pathways that together determine real-world Malaysian market access.

How much does healthcare market research cost in Malaysia?

Custom healthcare market research in Malaysia varies by scope, methodology, therapeutic area, and respondent type. Specialist physician surveys at university and tertiary hospitals and KOL mapping programmes cost more due to limited respondent availability, while online consumer and patient studies are typically more cost-efficient. Full mixed-method programs (HCP surveys + payer depth interviews + advisory board) carry a premium over single-method designs. MREC ethics compliance requirements add time and rigour compared to non-compliant alternatives. For an accurate estimate, scope is best discussed directly based on therapy area, sample, and methodology requirements.

Is BioNixus MREC-compliant for HCP research in Malaysia?

Yes. BioNixus designs Malaysian HCP and patient research to align with MREC (Medical Research and Ethics Committee, under the MOH) requirements where applicable, alongside appropriate institutional ethics review for university and tertiary hospital studies. This includes appropriate informed consent procedures, ethics review where required, PDPA (Personal Data Protection Act) compliant data privacy, and de-identified reporting. Ethics compliance is essential for credible research involving Malaysian HCPs, patients, and health system stakeholders, and is a prerequisite for robust pharmaceutical and biotech research programs.

What are the key Malaysian health systems and academic medical centres for KOL research?

The leading Malaysian academic and tertiary health systems for KOL research and specialist HCP access include: University of Malaya Medical Centre (UMMC / PPUM, Kuala Lumpur) — one of the leading academic medical centres in Malaysia; Universiti Sains Malaysia (USM) Hospital (Hospital USM, Kelantan) — a key academic health system in the north; Universiti Kebangsaan Malaysia (UKM) Medical Centre (HUKM / PPUKM, Kuala Lumpur) — a major teaching hospital; and the MOH (KKM) tertiary hospital network, including Hospital Kuala Lumpur and major state hospitals. For multi-specialty research, these university hospitals together with leading private hospital groups offer broad KOL access across Malaysia's key research and clinical centres.

Can Malaysian healthcare research connect to global benchmarking?

Yes. BioNixus designs Malaysian healthcare research to connect to global benchmarking programs — allowing pharmaceutical and biotech clients to compare Malaysian HCP attitudes, payer dynamics, and market access conditions directly against the USA, UK, France, Germany, Spain, Italy, Brazil, Saudi Arabia, the UAE, and other ASEAN markets using consistent survey instruments and analysis frameworks. Malaysia-specific adaptations (public-private payer segmentation, MaHTAS and FUKKM alignment, MOH and university hospital fieldwork) are layered within globally consistent methodologies, enabling Malaysia-specific insight within a global strategic context.

Related Resources

Pharmaceutical Market Research Malaysia

MREC-aligned pharmaceutical research covering HCP surveys, KOL mapping, payer and formulary research, and MaHTAS evidence strategy.

Top Market Research Companies Malaysia 2026

General and consumer market research firms across Malaysia for 2026.

Healthcare Market Research Malaysia

Comprehensive Malaysian healthcare market research overview — HCP surveys, payer and formulary research, health outcomes, and patient studies.

Healthcare Market Research

Global healthcare market research capabilities — HCP surveys, payer research, KOL mapping, and health outcomes studies across markets.

Plan Healthcare Market Research in Malaysia

BioNixus delivers MREC-compliant pharmaceutical and healthcare market research across Malaysia — HCP surveys at MOH and university hospitals, KOL mapping, payer and formulary research, MaHTAS/FUKKM evidence strategy, and public-private fieldwork. Global standards. In-market Malaysian execution.

Request a Proposal View Malaysian Research Capabilities